Literature DB >> 21187482

Down-regulation of Mus81 as a potential marker for the malignancy of gastric cancer.

Fan Wu1, Atsushi Shirahata, Kazuma Sakuraba, Yohei Kitamura, Tetsuhiro Goto, Mitsuo Saito, Kazuyoshi Ishibashi, Gaku Kigawa, Hiroshi Nemoto, Yutaka Sanada, Kenji Hibi.   

Abstract

BACKGROUND: The Mus81 gene encodes a critical endonuclease involved in DNA repair and tumor suppression. In the present study, the role of Mus81 in gastric cancer was explored.
MATERIALS AND METHODS: Mus81 expression in 53 cases of gastric cancer and the corresponding normal tissues was determined by quantitative real-time PCR. The correlations between Mus81 down-regulation and the clinicopathological data were also evaluated.
RESULTS: Mus81 expression was significantly lower in gastric cancer tissues than the corresponding normal tissues (p = 0.018) and the down-regulation of Mus81 occurred in 51% (27/53) of the gastric carcinomas. More importantly, Mus81 down-regulation correlated significantly to invasion depth (p = 0.015) and poorly-differentiated type (p = 0.016) of gastric cancer.
CONCLUSION: Mus81 might be a potential marker for the malignancy of gastric cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21187482

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  10 in total

1.  Rad54 and Mus81 cooperation promotes DNA damage repair and restrains chromosome missegregation.

Authors:  S El Ghamrasni; R Cardoso; L Li; K K N Guturi; V A Bjerregaard; Y Liu; S Venkatesan; M P Hande; J T Henderson; O Sanchez; I D Hickson; A Hakem; R Hakem
Journal:  Oncogene       Date:  2016-02-15       Impact factor: 9.867

2.  Up-regulated biglycan expression correlates with the malignancy in human colorectal cancers.

Authors:  Xiaohu Gu; Yegang Ma; Jingdong Xiao; Hongxin Zheng; Chun Song; Yuehua Gong; Xiaojing Xing
Journal:  Clin Exp Med       Date:  2011-08-31       Impact factor: 3.984

3.  Association study of genetic variation in DNA repair pathway genes and risk of basal cell carcinoma.

Authors:  Yuan Lin; Harvind S Chahal; Wenting Wu; Hyunje G Cho; Katherine J Ransohoff; Fengju Song; Jean Y Tang; Kavita Y Sarin; Jiali Han
Journal:  Int J Cancer       Date:  2017-05-31       Impact factor: 7.396

Review 4.  Helicobacter pylori infection and gastric carcinoma: Not all the strains and patients are alike.

Authors:  Natale Figura; Luigi Marano; Elena Moretti; Antonio Ponzetto
Journal:  World J Gastrointest Oncol       Date:  2016-01-15

Review 5.  Genetic aspects of gastric cancer instability.

Authors:  Petra Hudler
Journal:  ScientificWorldJournal       Date:  2012-04-19

6.  Temporal regulation of the Mus81-Mms4 endonuclease ensures cell survival under conditions of DNA damage.

Authors:  Irene Saugar; María Victoria Vázquez; María Gallo-Fernández; María Ángeles Ortiz-Bazán; Mónica Segurado; Arturo Calzada; José Antonio Tercero
Journal:  Nucleic Acids Res       Date:  2013-07-30       Impact factor: 16.971

7.  Mus81 knockdown improves chemosensitivity of hepatocellular carcinoma cells by inducing S-phase arrest and promoting apoptosis through CHK1 pathway.

Authors:  Fan Wu; Wei-Jia Chen; Lun Yan; Guo-Qian Tan; Wei-Tao Li; Xuan-Jin Zhu; Xiao-Chuan Ge; Jian-Wei Liu; Bai-Lin Wang
Journal:  Cancer Med       Date:  2015-12-29       Impact factor: 4.452

8.  Upregulation of long noncoding RNA Xist promotes proliferation of osteosarcoma by epigenetic silencing of P21.

Authors:  Tianyang Xu; Wenwei Jiang; Lin Fan; Qiuming Gao; Guodong Li
Journal:  Oncotarget       Date:  2017-09-08

9.  Translational study identifies XPF and MUS81 as predictive biomarkers for oxaliplatin-based peri-operative chemotherapy in patients with esophageal adenocarcinoma.

Authors:  T P MacGregor; R Carter; R S Gillies; J M Findlay; C Kartsonaki; F Castro-Giner; N Sahgal; L M Wang; R Chetty; N D Maynard; J B Cazier; F Buffa; P J McHugh; I Tomlinson; M R Middleton; R A Sharma
Journal:  Sci Rep       Date:  2018-05-08       Impact factor: 4.379

10.  Expression of MUS81 Mediates the Sensitivity of Castration-Resistant Prostate Cancer to Olaparib.

Authors:  Lifeng Gong; Yu Tang; Li Jiang; Wei Tang; Shengjun Luo
Journal:  J Immunol Res       Date:  2022-07-21       Impact factor: 4.493

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.